HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alan P Kozikowski Selected Research

Ether (Diethyl Ether)

9/2007Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.
3/2006Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.
4/2004Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues.
2/2003Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alan P Kozikowski Research Topics

Disease

31Neoplasms (Cancer)
01/2020 - 04/2002
10Neurodegenerative Diseases (Neurodegenerative Disease)
01/2021 - 02/2006
9Tuberculosis (Tuberculoses)
01/2013 - 10/2008
8Pancreatic Neoplasms (Pancreatic Cancer)
07/2021 - 03/2008
8Alzheimer Disease (Alzheimer's Disease)
06/2011 - 01/2003
7Schizophrenia (Dementia Praecox)
10/2017 - 05/2004
7Prostatic Neoplasms (Prostate Cancer)
07/2014 - 04/2002
5Extensively Drug-Resistant Tuberculosis
05/2020 - 04/2009
5Infections
01/2017 - 10/2009
5Cocaine-Related Disorders (Cocaine Addiction)
08/2005 - 07/2002
4Melanoma (Melanoma, Malignant)
01/2020 - 11/2012
4Traumatic Brain Injuries (Traumatic Brain Injury)
08/2008 - 03/2003
3Mental Disorders (Mental Disorder)
05/2020 - 02/2008
3Central Nervous System Diseases (CNS Diseases)
10/2014 - 11/2004
3Bipolar Disorder (Manic Depressive Psychosis)
09/2011 - 02/2006
3Coinfection
01/2011 - 10/2009
3Hypoxia (Hypoxemia)
04/2010 - 09/2002
3Nervous System Diseases (Neurological Disorders)
12/2008 - 06/2004
2Fragile X Syndrome (Martin Bell Syndrome)
01/2021 - 01/2019
2Peripheral Nervous System Diseases (PNS Diseases)
01/2020 - 01/2018
2Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy)
01/2018 - 02/2016
2Obesity
10/2017 - 12/2015
2Catalepsy
10/2017 - 01/2016
2Substance-Related Disorders (Drug Abuse)
12/2015 - 02/2006
2Seizures (Absence Seizure)
03/2013 - 09/2008
2Spinal Muscular Atrophy (Progressive Muscular Atrophy)
01/2012 - 05/2009
2Mania (Manias)
09/2011 - 07/2007
2Cognitive Dysfunction
06/2011 - 07/2004
2Neglected Diseases
10/2009 - 02/2008
2Inflammation (Inflammations)
05/2007 - 12/2004
2Pain (Aches)
05/2007 - 03/2004
2Carcinogenesis
05/2005 - 04/2003
1Type 2A Charcot-Marie-Tooth disease
01/2021
1Rare Diseases (Rare Disease)
01/2019
1Neurobehavioral Manifestations
10/2017
1Weight Loss (Weight Reduction)
10/2017

Drug/Important Bio-Agent (IBA)

22Pharmaceutical PreparationsIBA
05/2020 - 08/2002
13LigandsIBA
02/2020 - 01/2003
11Histone Deacetylase 6IBA
01/2021 - 11/2012
8Histone Deacetylase InhibitorsIBA
10/2017 - 05/2005
7Proteins (Proteins, Gene)FDA Link
01/2016 - 02/2003
6Histone Deacetylases (Histone Deacetylase)IBA
10/2017 - 03/2008
5Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)IBA
12/2008 - 04/2002
4Glycogen Synthase (Synthase I)IBA
07/2021 - 07/2007
4Biological ProductsIBA
11/2009 - 01/2003
4Ether (Diethyl Ether)IBA
09/2007 - 02/2003
4Phosphatidylinositols (Phosphatidylinositol)IBA
09/2007 - 02/2003
4LipidsIBA
09/2007 - 02/2003
3TubulinIBA
05/2020 - 01/2018
3Glycogen Synthase Kinase 3IBA
11/2019 - 01/2012
3Glycogen Synthase KinasesIBA
11/2019 - 04/2009
3Protein Isoforms (Isoforms)IBA
10/2017 - 06/2009
3Serotonin (5 Hydroxytryptamine)IBA
10/2017 - 06/2004
3Rad51 RecombinaseIBA
11/2016 - 01/2013
3EnzymesIBA
01/2016 - 07/2007
3AntigensIBA
12/2012 - 06/2005
3Urea (Carbamide)FDA LinkGeneric
11/2012 - 03/2004
3Therapeutic UsesIBA
06/2011 - 07/2004
3Glycogen Synthase Kinase 3 betaIBA
04/2009 - 02/2006
3Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA
02/2006 - 09/2002
3Cocaine (Cocaine HCl)IBA
08/2005 - 07/2002
2SW-100IBA
01/2021 - 01/2019
2Phosphotransferases (Kinase)IBA
11/2019 - 02/2003
2Small Interfering RNA (siRNA)IBA
11/2019 - 01/2012
2N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
10/2017 - 01/2008
2Mycolic Acids (Mycolic Acid)IBA
01/2017 - 01/2013
2DNA (Deoxyribonucleic Acid)IBA
11/2016 - 07/2014
2Neuroprotective AgentsIBA
01/2014 - 03/2003
2Histones (Histone)IBA
01/2014 - 08/2008
2maleimideIBA
06/2013 - 01/2012
2LithiumIBA
06/2013 - 07/2007
2Membrane Proteins (Integral Membrane Proteins)IBA
12/2012 - 06/2005
2huperzine AIBA
06/2011 - 09/2008
2EstersIBA
10/2010 - 09/2003
2AcidsIBA
10/2010 - 01/2006
2AmidesIBA
02/2010 - 09/2003
2RadiopharmaceuticalsIBA
05/2008 - 06/2005
2Phencyclidine (Angel Dust)IBA
01/2008 - 05/2004
2Protein Kinase CIBA
03/2006 - 09/2003
2Amyloid Precursor Protein Secretases (beta-Secretase)IBA
03/2006 - 01/2003
2Hormones (Hormone)IBA
06/2005 - 09/2003
2DiketopiperazinesIBA
03/2003 - 03/2003
21-ARA-35bIBA
03/2003 - 03/2003
2DipeptidesIBA
03/2003 - 03/2003
11,2,3,4-tetrahydroquinolineIBA
01/2021
1OxadiazolesIBA
02/2020
1GemcitabineFDA Link
11/2019
1Aurora KinasesIBA
04/2019
1Protein Kinase InhibitorsIBA
04/2019
1Glycine-tRNA LigaseIBA
01/2018
14- ((1- butyl- 3- phenylureido)methyl)- N- hydroxybenzamideIBA
10/2017
1Amphetamine (Amfetamine)FDA LinkGeneric
10/2017
1lorcaserinIBA
10/2017
1Serotonin 5-HT2 Receptor AgonistsIBA
10/2017
1Dopamine (Intropin)FDA LinkGeneric
10/2017
1Antipsychotic Agents (Antipsychotics)IBA
10/2017

Therapy/Procedure

19Therapeutics
01/2019 - 02/2003
4Drug Therapy (Chemotherapy)
07/2021 - 01/2017
1Immunotherapy
01/2020
1Transplantation
01/2017